Classificazione anatomo-patologica nei RCC Matteo Brunelli. Department of Pathology and Diagnostic, University di Verona, Italy
|
|
|
- Loraine Walsh
- 8 years ago
- Views:
Transcription
1 Classificazione anatomo-patologica nei RCC Matteo Brunelli Department of Pathology and Diagnostic, University di Verona, Italy
2 WHO 2004 AFIP 2004 =
3 ISUP Vancouver Classification 2013
4 5 newentities 3 emerging
5 WHO % 15% 5% 5%
6 GENETIC HISTOTYPES Clear cell CD10 3/3p Papillary CK Chromophobe PV 6 Oncocytoma S100A1 6-17
7 HISTOTYPES New renal histotypes: CLEAR CELL PAPILLARY RCC TUBULOCYSTIC CARCINOMA ACQUIRED CYSTIC DISEASE (ACD)-ASSOCIATED RCC TANSLOCATION RENAL CELL CARCINOMAs THYROID-LIKE FOLLICULAR CARCINOMA Hybrid oncocytic chromophobic tumor
8 Clear cell papillary RCC CEP3 / 3p CEP7 / CEP17 FISH ICH 7 17 Y 3p CD10 AMACR CK7 normal neg neg + CK7 Gobbo et al. Am J Surg Pathol.2008;32:1239
9 Clear cell papillary RCC CGH MS MLPA Chromosome 3 Methylation status VHL ( ) VHL ( ) Copy number VHL ( ) VHL ( )
10 GENE EXPRESSION PROFILE cca ccb Cluster3 Cluster3 Cluster3 Cluster3
11 Clear cell papillary RCC CGH CK7 34βE12 Chromosome 3 CD10
12 Should Clear Cell Papillary Renal Cell Carcinoma be Recognized as an Entity at this time? 1. Yes 85% 2. No 3. Uncertain even with personal experience/ knowledge 4. Not enough personal experience/knowledge 10% 2% 3% ISUP Consensus Conference, Vancouver 18 march 2012
13 Clear cell papillary RCC NUMBER OF CASES: 82 (FREQUENCY: 0.8%, 23/3000) CASES IN END STAGE RENAL DISEASE: 51 CASES NOT IN END STAGE RENAL DISEASE: 31 MEAN AGE: 56 CASES IN END STAGE RENAL DISEASE: 55 CASES NOT IN END STAGE RENAL DISEASE: 59 M/F: 1,5/1 MULTIFOCALITY: 9 CASES 5 CASES IN END STAGE RENAL DISEASE TUMOR DIMENSION: 3 cm CASES IN END STAGE RENAL DISEASE: 2,5 cm CASES NOT IN END STAGE RENAL DISEASE: 3,4 cm GRADING ALL TUMORS G1-G2 PATHOLOGIC STAGE: pt1 ALL TUMORS pt1a EXCEPT 3 CASES pt1b FOLLOW-UP (1-85 month) ALL CASES WITHOUT EVIDENCE OF RECURRENCES Tikoo et al. Am J Surg Pathol.2006;30:141 Gobbo et al. Am J Surg Pathol.2008;32:1239 Nouh et al. BJUI 2009;105: 620 Aydin et al Am J Surg Pathol 2010;34:1608 Rohan et al. Mod Pathol 2011;24:1207 Adam et al. Histopathology 2011; 58: 1064
14 WHO 200 Clear cell papillary renal cell carcinoma / tumor
15
16
17 CEP3 / 3p
18 RCC with prominent leiomyomatous proliferation CGH MS MLPA Methylation status Copy number VHL ( ) VHL ( ) VHL ( ) VHL ( ) 6 NA 0.33 NA Chromosome 3 SEQUENCING ANALYSIS 6 Exon1 Exon 2 Exon 3
19 Renal angiomyoadenomatous tumor (RAT) CD10 CK7 VHL -- / + ++ WT Sm Act Michal et al. Virchows Arch, 2011, 754:89-99
20 Do you think Clear Cell Papillary Renal Cell Carcinoma and RAT are related? 1. They are probably the same entity 2. They are probably different entities 3. Uncertain even with personal experience/knowledge 4. Not enough personal experience/knowledge 52% 32% 8% 8% ISUP Consensus Conference, Vancouver 18 march 2012
21 NEW HISTOTYPES
22 UNUSUAL HISTOTYPES New renal histotypes: CLEAR CELL PAPILLARY RCC TUBULOCYSTIC CARCINOMA ACQUIRED CYSTIC DISEASE (ACD)-ASSOCIATED RCC TANSLOCATION RENAL CELL CARCINOMAs THYROID-LIKE FOLLICULAR CARCINOMA
23 2012
24 MiTF/TFE family renal translocation carcinomas t(x;1) t(x;17) t(6;11)
25 MiTF/TFE family renal translocation carcinomas Fusion ASPL-TFE3 PRCC-TFE3 PSF-TFE3 NonO-TFE3 CLTC-TFE3?-TFE3 Alpha-TFEB Translocation t(x;17)(p11.2;q25) t(x;1)(p11.2;q21) t(x;1)(p11.2;p34) inv(x)(p11.2;q12) t(x;17)(p11.2;q23) t(x;3)(p11.2;q23) t(6;11)(p21;q12)
26 WHO 200 MITF/TFE family renal translocation carcinomas Clear cell papillary renal cell carcinoma / tumor
27 Translocation carcinomas Xp11.2 TFE3 T(6;11) TFEB OVEREXPRESSION TFE3 immunohistochemical detection TFEB Pecciarini L, Cangi MG, Lo Cunsolo C, Macri' E, Dal Cin E, Martignoni G, Doglioni C. Characterization of t(6;11)(p21;q12) in a renalcell carcinoma of an adult patient. Genes Chromosomes Cancer. 2007;46:419
28 TFE3 and TFEB IHC can sometimes be problematic 1. nonstandardized or excessive/inadequate fixation may result in false negative results 1 2. weak staining is difficult to interpret; a recent study 2 has suggested that such cases do not show TFE3 fusions, supporting the original scoring system proposed by Argani et al 1 which classifies weak staining as a negative result 3. oversensitive antigen retrieval techniques can result in detection of native TFE3, which is ubiquitously expressed 4. lot-to-lot differences in the antibody are another potential source of variability 1 Argani P, Lal P, Hutchinson B, et al. Am J Surg Pathol Zhong et al. Abstract n USCAP 2009
29 Cathepsin K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas Case # Genetic Cathepsin K 1 t(x;1)(p11;q21) 90% 2 t(x;1)(p11;q21) 100% 3 t(x;1)(p11;q21) 80% 4 t(x;1)(p11;q21) 90% 5 t(x;1)(p11;q21) 70% 6 t(x;1)(p11;p34) Neg 7 t(x;1)(p11;p34) 80% 8 t(x;1)(p11;p34) Neg 9 t(x;17)(p11;q25) Neg 10 t(x;3)(p11;q23) Neg 11 t(6;11)(p21;q12) 100% 12 t(6;11)(p21;q12) 90% 13 t(6;11)(p21;q12) 80% 14 t(6;11)(p21;q12) 100% 15 t(6;11)(p21;q12) 100% 16 t(6;11)(p21;q12) 90% 17 t(6;11)(p21;q12) 90% Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan CC, Netto G, Doglioni C, Hes O, Argani P, Chilosi M Modern Pathology 2009
30
31 FISH and TFE3 Xp11 Xp11 Translocation Renal Cell Carcinoma TFE3 (Xp11) break apart, Kreatech Diagnostics
32 Translocation RCC Xp11
33
34 Translocation RCC t(6;11) Ck AE1-3 HMB45 Argani et al. Am J Pathol 2001;158:2089
35 When should TFE3 and TFEB analysis (IHC and/or FISH) be requested to identify translocation RCC cases? 1. When RCC is diagnosed in a patient under 30 years of age 80% 2. When the morphology is suggestive of translocation RCC in a patient older than 30 year of age 3. Both A and B 4. I do not request for TFE3 or TFEB immunostaining 3% 12% 6% ISUP Consensus Conference, Vancouver 18 march 2012
36 Should t(6;11) RCC be Recognized as an Entity at this time? 1. Yes, include it with Xp11 RCC under MiT Family Translocation RCC 69% 2. Yes, make it its own category 3. No 4. Uncertain even with personal experience/knowledge 5. Not enough personal experience/knowledge 17% 2% 2% 10% ISUP Consensus Conference, Vancouver 18 march 2012
37 Tubulocystic carcinoma
38 Tubulocystic carcinoma RACEMASE CEP 7/17
39 Should Tubulocystic-RCC be recognized as an entity at this time? 1. Yes 73% 2. No 3. Uncertain even with personal experience/ knowledge 4. Not enough personal experience/knowledge 5% 7% 14% ISUP Consensus Conference, Vancouver 18 march 2012
40 Differentialdiagnosis Clear cell RCC Papillary RCC Pseudopapillary architecture Clear cytoplasm
41 Cellule Chiare Papillare Cromofobo Oncocitoma CD10 racemasi PV S100A1 PV Ck7 S100A1 Ck7 Martignoni G et al. Role of molecular markers in the diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol; in press
42 GENETIC HISTOTYPES Carcinoma cromofobo (variante eosinofila) Oncocitoma CEP cromosoma 6 Brunelli M. Mod Pathol 2005;18:161-9.
43 Markers diagnostici, prognostici e predittivi di risposta terapueutica
44 METHODS ph mtor ccrcc
45 METHODS mtor Rene normale (green) ccrcc (green)
46 SENSIBILITY AND SPECIFICITY
47 Clear cell renal cell carcinoma 3p deletion VHL deletion
48
49 Biological reasons Siebert et al. J Urol 1998;160:534
50 ALK renalcellcarcinoma
51 Conclusions New entities ISUP Vancouver Classification Rare entities: ALK renal cell carcinoma Immunohistochemistryand molecularanalysis: differential diagnosis Classificazione molecolare: triple negative clear cell renalcellcarcinoma (VHL, 3p, methylation), carcinomi mtor positivi
52 Conclusions
RENAL CELL CARCINOMA EPIDEMIOLOGY
RENAL CELL CARCINOMA: THE 2012 ISUP VANCOUVER CLASSIFICATION David Grignon MD, Indiana University, Indianapolis, IN RENAL CELL CARCINOMA EPIDEMIOLOGY Siegel et al. CaA Cancer J Clin 63:11-30, 2013 1 EPITHELIAL
Epithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities
Pathology of Renal Neoplasia Epithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities Wael A Sakr, MD Wayne State University School of Medicine CURRENT CLASSIFICATION = EPITHELIAL
Renal Pathology Update. Sundus Hussein MD, FRCPC
Renal Pathology Update Sundus Hussein MD, FRCPC Case History A 45 year old male with incidentally discovered a 3.5 x 3.9 x 2.7 cm renal mass Handling partial nephrectomy Handling partial nephrectomy
MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER
Renal tumours WHO 4 MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours G. KOVACS A CLASSIFICATION BASED ON UNDERSTANDING THE GENETIC
Something Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
ONCOLOGIA E RENE 6 novembre 2014
ONCOLOGIA E RENE 6 novembre 2014 CARCINOMA DEL RENE: ASPETTI ANATOMO-PATOLOGICI Guido Martignoni Dipartimento di Patologia e Diagnostica Università di Verona ISUP Consensus Conference WH 2004 on Adult
Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
Emerging and Newly Recognized Subtypes of Renal Tumors: Keys to Recognition Session 1006
Emerging and Newly Recognized Subtypes of Renal Tumors: Keys to Recognition Session 1006 Sean R. Williamson, MD Senior Staff Pathologist, Henry Ford Health System Clinical Assistant Professor of Pathology,
KIDNEY CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATION / TFE3 (ASPL-TFE3) GENE FUSION
Case Report International Braz J Urol Official Journal of the Brazilian Society of Urology KIDNEY CA AND Xp11.2 TRANSLOCATION Vol. 31 (3): 251-255, May - June, 2005 KIDNEY CARCINOMA ASSOCIATED WITH XP11.2
Emerging Subtypes in Renal Cancer. Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology dhansel@ucsd.
Emerging Subtypes in Renal Cancer Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology dhansel@ucsd.edu Some General Comments Fuhrman nuclear grading clear cell
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
The role of Immunohistochemistry in diagnosis of renal cell carcinoma subtypes.
Asian Archives of Pathology 2013; Vol. 9 No.1, 9-16 Original articles The role of Immunohistochemistry in diagnosis of renal cell carcinoma subtypes. Sutthiporn Namnak, BSc *, Wipawee Kittikowit, MD *,
Review of renal carcinoma with t(6;11)(p21;q12) with focus on clinical and pathobiological aspects
Histol Histopathol (2013) 28: 685-690 http://www.hh.um.es Histology and Histopathology Cellular and Molecular Biology Review Review of renal carcinoma with t(6;11)(p21;q12) with focus on clinical and pathobiological
Histologic Subtypes of Renal Cell Carcinoma
Histologic Subtypes of Renal Cell Carcinoma M. Scott Lucia, MD Associate Professor Chief of Genitourinary and Renal Pathology Director, Prostate Diagnostic Laboratory Dept. of Pathology University of Colorado
Translocation Renal Cell Carcinomas
Translocation Renal Cell Carcinomas Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Kidney cancer is not a single disease Clear cell (75%)
RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE
RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours
Renal Neoplasms: An Update on Immunohistochemical and Histochemical Features
Application Renal Neoplasms: An Update on Immunohistochemical and Histochemical Features Stephen M. Bonsib, MD Ami Bhalodia, MD Albert and Harriet Smith Professor and Chair Louisiana State University Health
New Concepts and Refinements to. Existing WHO (2004) Renal Cell. Tumor Categories In Adults
New Concepts and Refinements to Existing WHO (2004) Renal Cell Tumor Categories In Adults Dr Varsha Manucha Assistant Professor Department of Pathology and Laboratory Medicine Temple University Hospital
Translocation Renal Cell Carcinomas: Molecular insights and Future Directions
Translocation Renal Cell Carcinomas: Molecular insights and Future Directions Gabriel G. Malouf, MD, PhD Assistant professor Department of medical oncology Pitié-Salpêtrière Hospital, Paris, France Background
Recent Advances in Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE Gene Fusions
North American Journal of Medicine and Science Jan 2012 Vol 5 No.1 43 Review Recent Advances in Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE Gene Fusions Yunguang Liu, MD, PhD; 1 Bo Xu,
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc
Keywords pediatric renal cell carcinoma, TFE3, Xp11.2 translocation carcinomas, prognosis
Xp11.2 Translocation Renal Cell Carcinomas Have a Poorer Prognosis Than Non-Xp11.2 Translocation Carcinomas in Children and Young Adults: A Meta-analysis International Journal of Surgical Pathology 18(6)
Histopathology and prognosis in renal cancer
Histopathology and prognosis in renal cancer Granular cell Granular cell Granular cell Granular cell Clear cell Chromophobe cell Papillary type 2 Luca Mazzucchelli Istituto cantonale di patologia, Locarno
Renal Tumors with Eosinophilic Cytoplasm: A Contemporary Approach to a Challenging Differential Diagnosis
Renal Tumors with Eosinophilic Cytoplasm: A Contemporary Approach to a Challenging Differential Diagnosis Jesse K. McKenney, MD Director, Urologic Pathology Stanford University The modern classification
Renal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases
The Korean Journal of Pathology 2005; 39: 406-11 Renal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases Sanghui Park Ji-Eun Kwon Yeon-Lim
Original Article Clear cell papillary renal cell carcinoma: a clinicopathologic analysis of 6 cases
Int J Clin Exp Pathol 2015;8(5):4595-4599 www.ijcep.com /ISSN:1936-2625/IJCEP0005852 Original Article : a clinicopathologic analysis of 6 cases Wen-Xiu Yan 1, Wen-Rong Cao 1, Jun Zhao 1, Wei Zhang 2, Xue-Li
2009 update on the classification of renal epithelial tumors in adults
International Journal of Urology (2009) 16, 432 443 doi: 10.1111/j.1442-2042.2009.02302.x Review Article 2009 update on the classification of renal epithelial tumors in adults Antonio Lopez-Beltran, 1
Molecular heterogeneity of TFE3 activation in renal cell carcinomas
308 & 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 Molecular heterogeneity of TFE3 activation in renal cell carcinomas Stephan Macher-Goeppinger 1,2, Wilfried Roth 1,2, Nina Wagener 3, Markus
JOURNAL OF CLINICAL ONCOLOGY DIAGNOSIS IN ONCOLOGY
VOLUME 28 NUMER 34 DECEMER 1 2010 JOURNL OF CLINICL ONCOLOGY DIGNOSIS IN ONCOLOGY Renal Cell Carcinoma With t(6;11) Translocation: Patient Case With a Novel lpha- Fusion Point Renal cell carcinoma (RCC)
Practical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
Introduction. Wu A, Kunju L P, Cheng L & Shah R B (2008) Histopathology 53, 533 544
Histopathology 2008, 53, 533 544. DOI: 10.1111/j.1365-2559.2008.03151.x Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma. Melissa Price, MD Aoife Kilcoyne, MD Mukesh G.
CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma Melissa Price, MD Aoife Kilcoyne, MD Mukesh G. Harisinghani, MD Disclosures Neither I nor my immediate family members have
The WHO Classification of Renal Tumors and Common Issues in TNM Staging for Renal Cell Carcinoma
The WHO Classification of Renal Tumors and Common Issues in TNM Staging for Renal Cell Carcinoma Steven Shen, M.D.,Ph.D. Staff Pathologist and Assistant Member The Methodsit Hospital and Research Institute
XP11.2 Translocation renal cell carcinoma: Clinical experience of Taipei Veterans General Hospital
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 500e504 Original Article XP11.2 Translocation renal cell carcinoma: Clinical experience of Taipei Veterans
Outline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
BRAF as a prognostic marker in papillary thyroid cancer
12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia
Diagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
CASE REVIEW. Oncocytic Renal Neoplasms. A Molecular Approach to a Common Diagnostic Challenge
CASE REVIEW Oncocytic Renal Neoplasms A Molecular Approach to a Common Diagnostic Challenge Federico A. Monzon, MD,* Steven S. Shen, MD, PhD,* Bonnie Kemp, MD, Karla Alvarez, BSc, and Alberto G. Ayala,
Recently described subtypes of renal tumours (adults)
Recently described subtypes of renal tumours (adults) Dr Jonathan H Shanks The Christie NHS Foundation Trust, Manchester, UK Malignant renal tumours - adults Renal cell carcinoma - Conventional (clear
Renal Cell Carcinoma Detection of PRCC-TFE3 and Alpha-TFEB Gene Fusions Using RT-PCR on Tissues (odes 60153 and 60154) Notice of Assessment
Renal Cell Carcinoma Detection of PRCC-TFE3 and Alpha-TFEB Gene Fusions Using RT-PCR on Tissues (odes 60153 and 60154) Notice of Assessment June 2013 DISCLAIMER: This document was originally drafted in
Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology
Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
SEMESTER VI 3 RD YEAR PATHOLOGY KIDNEY TUMORS
SEMESTER VI 3 RD YEAR PATHOLOGY KIDNEY TUMORS LEARNING OBJECTIVES At the end of the lecture, students should be able to: Know the pathology of renal tumors. RENAL TUMORS RENAL PAPILLARY ADENOMA Common
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
Role of histopatological assessment of renal cancer specimen after radical and partial nephrectomy
Role of histopatological assessment of renal cancer specimen after radical and partial nephrectomy Dr hab. n. med. Agnieszka Korolczuk Joanna Irla Natalia Pieszek Monika Orzeł Dr hab. n. med. Justyna Szumiło
Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
<1 cm WDT-UMP, FT-UMP. Kakudo K et al, Pathol Int,2009, Endocr J, 2011 and Pathol Int, 2012
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
Renal Cell Carcinoma (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2365661/ Renal Cell Carcinoma (Event Driven) Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that
Tubulocystic Carcinoma of the Kidney, a Rare Distinct Entity
Tubulocystic Carcinoma of the Kidney, a Rare Distinct Entity 2 Shreenath Bishu, Laurie J. Eisengart and Ximing J. Yang * Department of Pathology, Northwestern University, Feinberg School of Medicine, Feinberg,
Gladwyn Leiman, MCCCh, FIAC, FRCPath Scott Anderson, MD
Cytology Works shop #5 Gladwyn Leiman, MCCCh, FIAC, FRCPath Scott Anderson, MD Disclosur re information The speakers have no relationship that represents a possible conflict of interest with respect to
- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa
- Slide Seminar - Endocrine pathology in non-endocrine organs Case 11 Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa Dept. of Pathology, Multimedica, Milan, Italy Dept. of Surgical and Morphological
Renal Tumors with Granular Cytoplasm: Clues to Accurate Diagnosis
Renal Tumors with Granular Cytoplasm: Clues to Accurate Diagnosis Current Issues in Surgical Pathology May 25, 2012 Jeffry P. Simko, PhD, MD Associate Professor Departments of Urology, Radiation Oncology
Immunohistochemical Analysis of Chromophobe Renal Cell Carcinoma, Renal Oncocytoma, and Clear Cell Carcinoma
Immunohistochemical Analysis of Chromophobe Renal Cell Carcinoma, Renal Oncocytoma, and Clear Cell Carcinoma An Optimal and Practical Panel for Differential Diagnosis Lina Liu, MD; Junqi Qian, MD; Harpreet
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
VHL and clear cell Renal Cell Carcinoma. Expression profiling reveals cell of origin. Renal Cell Carcinoma (RCC) Title. VHL syndrome hallmark cancer:
VHL and clear cell Renal Cell Carcinoma Gene expression profiles in renal cell carcinoma October 23, 2014 VHL syndrome hallmark cancer: Clear cell renal cell carcinoma (ccrcc) VHL mutations also a hallmark
March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,
Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,
Validation and utilization of a TFE3 breakapart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
Pradhan et al. Diagnostic Pathology (2015) 10:179 DOI 10.1186/s13000-015-0412-z RESEARCH Open Access Validation and utilization of a TFE3 breakapart FISH assay for Xp11.2 translocation renal cell carcinoma
Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD
20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,
Introduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
TFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY SYMBOL DEFINITIONS INTENDED USE PRINCIPLES AND PROCEDURES SUMMARY AND EXPLANATION
Rev. 0.0 TFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY Cat. No. Description 354R-14 0.1 ml, concentrate 354R-15 0.5 ml, concentrate 354R-16 1.0 ml, concentrate 354R-17 1.0 ml, predilute
Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Human Cancer Biology Clinical Cancer Research Genomic Heterogeneity of Translocation Renal Cell Carcinoma Gabriel G. Malouf 1, Federico A. Monzon 7,8,Jer^ome Couturier 10, Vincent Molinie 11, Bernard Escudier
How to report Upper GI EMR/ESD specimens
Section of Pathology and Tumour Biology How to report Upper GI EMR/ESD specimens Dr.H.Grabsch Warning. Most of the criteria, methodologies, evidence presented in this talk are based on studies in early
Principles And Procedures
Product Identification Cat. No. Description 45339 IMPATH TFE3 RTU R (MRQ-37) Symbol Definitions P A E S DOC# DIS ready-to-use ascites serum supernatant document number distributed by Intended Use This
From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes
ISSN 2154-4006 The Genetic Basis of Human Disease zbar Colloquium series on Series Editor: Michael Dean, Ph.D., Head, Human Genetics Section, Senior Investigator, Laboratory of Experimental Immunology
The develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
Immunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
Case of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
Beyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
Four Important Facts about Kidney Cancer
Volume Article.13-11 Publish Date: 24th June 2013 Author(s): MPUH - CRS Team Four Important Facts about Kidney Cancer ARTICLE hhh Muljibhai Patel Urological Hospital (MPUH) Centre For Robotic Surgery (CRS)
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
Outcome prediction for renal cell carcinoma (RCC)
SPECIAL ARTICLE The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters Brett Delahunt, MD,* John C. Cheville, MD,w Guido Martignoni,
BRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
Original Article Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization study
Int J Clin Exp Pathol 2014;7(1):236-245 www.ijcep.com /ISSN:1936-2625/IJCEP1309003 Original Article Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization
A 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
Identifying and extracting malignancy types in cancer literature
Identifying and extracting malignancy types in cancer literature Yang Jin 1, Ryan T. McDonald 2, Kevin Lerman 2, Mark A. Mandel 4, Mark Y. Liberman 2, 4, Fernando Pereira 2, R. Scott Winters 3 1, 3,, Peter
microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS
microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS 1st International Congress on Controversies in Personalized Oncology (CONPO) BARCELONA, SPAIN MARCH
Pathology of Renal Cell Carcinoma
Pathology of Renal Cell Carcinoma Ming Zhou and Huiying He 2 Arising from the renal tubular epithelial cells, renal cell carcinoma (RCC) accounts for more than 90% of primary kidney tumors in adults. It
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules KIDNEY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
New and old Hereditary forms of Renal Cell Carcinoma. Maria J Merino MD National Cancer Institute Bethesda, MD
New and old Hereditary forms of Renal Cell Carcinoma. Maria J Merino MD National Cancer Institute Bethesda, MD Renal cell carcinoma affects approximately 30,000 individuals per year in the United States
Case based applications part III
Case based applications part III Los Angeles Society Of Pathologists January 25, 2014 Sanja Dacic, MD, PhD University of Pittsburgh Medical Center 1 CASE 1 A 44-year-old woman with multiple lung nodules.
micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
Notice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada achurg@mail.ubc.ca Notice of Faculty Disclosure In accordance with
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in